Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PW Medtech Group Ltd. ( (HK:1358) ) has issued an announcement.
PW Medtech Group Limited has warned that its net profit for 2025 is expected to fall to between RMB120 million and RMB147 million, down 24% to 38% from 2024, with profit attributable to shareholders dropping 32% to 45% to a range of RMB83 million to RMB102 million. The company attributed the sharp earnings decline mainly to reduced sales in its infusion set segment following near-full implementation of centralized procurement policies in China, and cautioned investors as it prepares to release audited 2025 results by the end of March 2026.
The anticipated profit contraction underscores the growing impact of China’s volume-based procurement on medical device manufacturers’ margins and revenue stability. For PW Medtech, the shift signals mounting operational and pricing pressure in one of its key product lines, raising concerns for shareholders over future growth prospects and the need to adapt its business mix or strategy in response to policy-driven market changes.
The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.
More about PW Medtech Group Ltd.
PW Medtech Group Limited is a Cayman Islands-incorporated medical technology company listed in Hong Kong, focused on healthcare products including infusion sets. The group operates in mainland China’s medical devices market, where its infusion set business is exposed to national centralized procurement policies that pressure pricing and sales volumes.
YTD Price Performance: 0.78%
Average Trading Volume: 482,588
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.91B
See more data about 1358 stock on TipRanks’ Stock Analysis page.